Cystic fibrosis has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections. However, the physiological mechanisms for this reduced exercise capacity are unknown. The investigators recently published the first evidence of systemic vascular dysfunction in patients with CF. Therefore, it is reasonable to suspect that the blood vessels are involved with exercise intolerance in CF. This study will look at how and if oxidative stress contributes to both artery dysfunction and exercise intolerance in CF.
Cystic Fibrosis (CF) is the most common fatal genetic disease in North America. The most disturbing aspect of CF is the associated premature death, most often due to respiratory complications. Clinical manifestations of CF include not only lung dysfunction, but many other systemic consequences as well. Systemic oxidative stress and exercise intolerance are established phenotypes in patients with CF. Additionally, for the first time the investigators have recently published the presence of systemic endothelial dysfunction in a cohort of young patients with CF who exhibited normal oxygen saturation and spirometric function. Exercise intolerance, the limitation of the ability to perform exercise at the expected level, has been shown to predict mortality in patients with CF independent of lung function. Exercise capacity (VO2 peak), an objective measurement of exercise tolerance, drops approximately 5-8% per year in patients with CF. This excessive decay in exercise capacity not only leads to more pulmonary infections and deterioration of lung function, it represents a 5-8 fold decline compared to healthy sedentary adults. Preventing the excessive annual reduction in exercise capacity is essential to increasing the quality of life and longevity of patients with CF. However, a critical barrier to improving exercise capacity in CF is the investigators lack of knowledge regarding the different physiological mechanisms that contribute to exercise intolerance. It is important to emphasize that decreases in lung function (FEV1) do not always contribute to reductions in VO2 peak. Furthermore, less than 2% of patients who have an FEV1 greater than 50% predicted will have a significant drop in hemoglobin oxygen saturation (SpO2) during maximal exercise. These data suggest that mechanisms other than lung function induced hypoxemia may be contributing to exercise intolerance in patients with CF.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
13
Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.
Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
Georgia Prevention Institute
Augusta, Georgia, United States
Acute Change in Flow mediated dilation
Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
Time frame: Change from baseline (2 hours)
Chronic Change in Flow mediated dilation
Flow-Mediated Dilation will be determined at baseline, week 4, week 8 and week 12.
Time frame: Baseline, week 4, week 8, and week 12
Acute Change in exercise capacity (VO2 peak)
Subjects will perform a baseline maximal exercise capacity test and on a separate visit perform a maximal exercise capacity test 2 hours following acute antioxidant treatment
Time frame: Baseline and 2 hours following acute antioxidant treatment
Chronic Change in exercise capacity (VO2 peak)
Subjects will perform a maximal exercise capacity test at baseline, week 4, week 8, and week 12.
Time frame: Baseline, week 4, week 8, and week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.